**Lightspeed India Exits Innovaccer with Profitable Return**
**Meta Description:** Lightspeed India has successfully exited its investment in Innovaccer, achieving over 30% returns amid evolving healthcare AI trends.
**URL Slug:** lightspeed-india-exits-innovaccer
**BENGALURU**: Lightspeed India has divested its stake in healthcare artificial intelligence (AI) firm Innovaccer earlier this year, as confirmed by sources familiar with the situation. The venture capital firm achieved an internal rate of return (IRR) exceeding 30% on its investment, marking a successful exit for one of the company’s earliest institutional investors. According to one insider, “Lightspeed has been looking to exit for some time. They are fortunate to have realized a 30% return on what was expected to be a significant contributor to their fund.”
The decision to sell was significantly influenced by Kaiser Permanente’s entry into Innovaccer’s capitalization table. Kaiser Permanente is one of the largest healthcare providers in the U.S., integrating not-for-profit insurance plans with its own network of hospitals and healthcare professionals.
For Lightspeed, this investment represented an early bet on Innovaccer’s rapid valuation growth. The firm first invested in 2018 during Innovaccer’s $25 million Series B funding round, which was led by WestBridge Capital. The following year, Lightspeed participated in a $10 million extension of that round, led by M12, Microsoft’s venture arm.
Despite its initial promise, Innovaccer has faced challenges, with reports indicating that its technology has not fully met market demands and that the company has spread itself too thin across the healthcare software landscape. Innovaccer currently provides solutions across the healthcare value chain, catering to providers, customers, public health systems, and the life sciences sector.
Nevertheless, U.S. venture capital remains optimistic about niche healthcare AI applications, particularly in areas such as scribing—technology that utilizes AI to transcribe and summarize conversations, primarily in healthcare settings to aid in the creation of electronic health records.
In 2023 alone, several healthcare AI companies have secured significant funding, including Ambience Healthcare, which raised $243 million in a Series C round led by Oak HC/FT and Andreessen Horowitz, and Navina, which obtained $55 million from Goldman Sachs. Additionally, Sully.ai raised $21.8 million in a Series A round led by Amity Ventures.
Tiger Global Management joined Innovaccer’s capitalization table in October 2019, leading a $70 million Series C round alongside Steadview Capital. This investment was pivotal in helping Innovaccer achieve unicorn status, following a $105 million fundraising round that valued the company at $1.3 billion.
Innovaccer’s most recent financing occurred in January, when it secured $275 million in a Series F round from B Capital Group, Banner Health, Danaher Ventures, Generation IM, Kaiser Permanente, and M12. This round included both primary and secondary components, providing opportunities for exits.
**FAQ**
**What is Innovaccer known for?**
Innovaccer specializes in healthcare AI solutions, offering technology that supports healthcare providers, public health systems, and life sciences organizations in managing data and improving patient outcomes.